🇺🇸 FDA
Patent

US 8067390

Therapeutic targeting of interleukins using siRNA in neutral liposomes

granted A61KA61K45/06A61K9/127

Quick answer

US patent 8067390 (Therapeutic targeting of interleukins using siRNA in neutral liposomes) held by The Board of Regents of the University of Texas System expires Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Nov 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K45/06, A61K9/127, A61P, A61P37/06